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Background: Matrix metalloproteinase-9 (MMP-9) is an important member of the matrix metalloproteinase family
and is considered to be involved in the invasion and metastasis of cancer cells. This study analyzed the expression
of MMP-9 in colon cancer patients and the relationship between this expression and clinicopathological features
and survival.
Methods: We immunohistochemically investigated 68 specimens of colon cancer tissues and corresponding distal
normal mucosa tissues using MMP-9 antibody. Then, the correlation between MMP-9 expression and clinicopathological
features and its prognostic relevance were determined.
Results: The expression rate of MMP-9 in colon cancer tissues was significantly higher than that in distal normal mucosa
(69.1% versus 2.9%, P < 0.001). Significant correlations were only found between high levels of MMP-9 expression and
metastasis of lymph nodes and Dukes’ stage. Overexpression of MMP-9 was associated with shorter survival times in
univariate analysis. Multivariate analysis confirmed that MMP-9 expression was an independent prognostic factor.
Conclusions: MMP-9 is correlated with the metastasis of lymph nodes, and its elevated expression may be an adverse
prognostic indicator for the patients of colon cancer.
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Colon cancer is the most frequent digestive system cancer
in the world. It is also the third most common malignant
tumor in the United States. In 2012, the estimated new
cases of colon cancer were 103,170 throughout the country
[1]. With the development of economy and the changes in
dietary patterns, the incidence of colon cancer is also in-
creasing rapidly in China. Now, colon cancer is the fourth
most common malignant tumor and the third leading
cause of cancer death in Chinese people [2].
The invasion and metastasis of cancer cells always re-
sult in treatment failure. Extracellular matrix (ECM)* Correspondence: whzyyfjm@163.com; whzyyrzg@163.com
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unless otherwise stated.degradation is an important stage of tumor metastasis,
which is regulated with matrix metalloproteinases (MMPs)
[3,4]. The MMPs carry out the selective proteolytic deg-
radation of ECM, which is an imperative step for the mi-
gration and invasion of tumor cells. MMPs are divided
into six categories according to the specificity of their sub-
strates as follow: interstitial collagenases, gelatinases, stro-
melysins, matrilysins, membrane-type MMPs and others
[5]. MMP-9 is an important member of the gelatinases. It
is also called gelatinase B or 92 kDa type IV collagenase
[6]. The gene of MMP-9 is located in 20q11.2-q13.1.
MMP-9 can be involved in the development of several hu-
man malignancies, as degradation of collagen IV in the
basement membrane and the extracellular matrix facili-
tates tumor progression, including invasion, metastasis,
growth and angiogenesis [7].
However, the correlation between MMP-9 expression
and survival or prognosis in colon cancer is still incon-
clusive. Here, we immunohistochemically investigated 68d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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distal normal mucosa tissues. Then, the association of
MMP-9 expression with clinicopathologic features and
prognosis was analyzed by univariate and multivariate
analysis. The results of this study could provide new evi-
dence for the research of MMP-9 in colon cancer.Methods
Ethics statement
The study was approved by the Wuhan General Hospital
Ethical Committee. Written informed consent was ob-
tained from all participants.Patients and tissue samples
Colon cancer tissues and corresponding distal normal mu-
cosa tissues of 68 patients who were treated at Wuhan
General Hospital of Guangzhou Command PLA between
January 2005 and January 2007 served as the study mater-
ial. Diagnosis and staging were performed according to
the modified Dukes’ classification [8]. Forty-four patients
were men and 24 patients were women. The mean age
was 58 years with a range of 47 to 70 years. The depth of
invasion was classified as mucosal and submucosal mem-
brane layer, muscular layer and serosa layer. Tumors were
classified as well, moderately and poorly differentiated
adenocarcinomas. Lymph node metastasis happened in 27
patients, and the other 41 patients had no metastatic
lymph nodes. All patients were followed up for survival.
None of the patient underwent radiotherapy or chemo-
therapy before surgery. Formalin-fixed and paraffin-
embedded surgical tissue samples were collected from the
archives of the Department of Pathology, Wuhan General
Hospital of Guangzhou Command.Figure 1 Matrix metalloproteinase-9 (MMP-9) expression in colon can
expression of MMP-9 was detected in the cytoplasm by immunohistochem
colon cancer tissue (×400, SP method).Immunohistochemistry
The paraffin-embedded colon cancer tissues and corre-
sponding distal normal mucosal tissues were cut at 4 μm
and mounted on glass slides. Then, the slides were dewaxed
in xylene and rehydrated in ethanol, and treated with a so-
lution of peroxidase-blocking reagent (Dako, Glostrup,
Denmark) to exhaust endogenous peroxidase activity. They
were put in 0.01 mol/L citrate buffer at pH 6.0 for 15 mi-
nutes in an 800 W microwave oven and then left at room
temperature for 20 minutes to expose antigen hidden inside
the tissue due to formalin fixation. To inhibit nonspecific
antigen-antibody reactions possible in immunohistochemi-
cal staining, protein blocker (Research Genetics, Huntsville,
AL, USA) was used for 5 minutes, and the slides were
washed thoroughly with PBS buffer. Then the slides were
incubated overnight with the primary antibodies against
MMP-9 (1:500; mouse monoclonal antibody, sc-21733,
Santa Cruz Biotechnology, Inc., Santa Cruz, USA) at 4°
centigrade. Biotinylated goat anti-mouse secondary anti-
body (1:200; BA1001, Boster Bio-engineering Limited
Company, Wuhan, China) was applied for 20 minutes at
room temperature, followed by further washing with buf-
fer to remove unbound antibody. A complex of avidin
with horseradish peroxidase was then applied for 20 mi-
nutes at room temperature. For color development, the
slides were stained with 3,3′-diaminobenzidine tetrahy-
drochloride (DAB, Sigma-Aldrich, St Louis, MO, USA),
then counterstained with hematoxylin. A reddish brown
precipitate in the cytoplasm of cells indicated a positive re-
action. In each immunohistochemistry run, the positive
section provided by the reagent company served as the
positive control, and omission of the primary antibody
served as negative control. Immunohistochemistry stained
slides were reviewed by two investigators independently
blinded to all clinical data. A scoring system was used tocer tissues. A: Positive MMP-9 expression in colon cancer tissue. The
istry staining (×400, SP method). B: Negative MMP-9 expression in
Table 1 The correlation of matrix metalloproteinase-9




Positive cases χ2 P
Gender
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moderate; 3, strong) and the percentage of cells stained (0,
0%; 1, 1% to 5%; 2, 6% to 75%; 3, 76% to 100%). The final
score was determined by the combined staining score (ex-





<58 years 32 21
0.345 0.557
≥58 years 36 26
Tumor size
<5 cm 41 27
0.515 0.473
≥5 cm 27 20
Differentiated degree
Well differentiated 32 23
1.144 0.565Moderately differentiated 19 14
Poorly and undifferentiated 17 10Statistical analysis
MMP-9 expressions in colon carcinoma and normal mu-
cosa were compared by χ2 test. The χ2 test was also used to
examine MMP-9 expressions in various clinicopathological
characteristics. The univariate survival analysis and cumula-
tive survival curve were executed by Kaplan-Meier method.
The difference between the curves was analyzed by Log-
rank test. The multivariate survival analysis was exe-
cuted by Cox proportional hazard regression model. A
P value < 0.05 was considered statistically significant.
All statistical analyses were performed with SPSS 13.0
(SPSS Inc., Chicago, IL, USA).Infiltrative depth
Mucosa and submucosal layer 11 5
5.872 0.053Muscular layer 24 15
Serosa layer 33 27






Matrix metalloproteinase-9 expression in colon carcinoma
and distal normal mucosa
Positive MMP-9 expression was observed in 69.1% (47/68)
of the colon cancer tissues, and in 4.4% (3/68) of the distal
normal mucosal tissues (Figure 1). The expression of
MMP-9 was detected in the cytoplasm. The difference of
MMP-9 expression between colon cancer and distal normal





Table 2 Results of survival analysis for individual factors
Factor Log rank P
Matrix metalloproteinase-9 (MMP-9) expression 11.010 0.001*
Gender 0.520 0.471
Age 0.041 0.839
Tumor differentiation 0.055 0.814
Metastasis of lymph node 8.687 0.003*
Infiltrative depth 6.141 0.013*
Dukes’ stage 11.831 0.001*
*Statistically significant.Correlation of matrix metalloproteinase-9 expression and
clinicopathological features in colon cancer
When comparing the MMP-9 status with clinicopatholog-
ical variables, we found significant positive correlations
between MMP-9 expression and lymph node metastasis
(P = 0.020), and Dukes’ stage (P = 0.029) (Table 1). Kaplan-
Meier analysis showed that the differences of survival in
the MMP-9 expression group and the Dukes’ stage group
were highly statistically significant (Log-rank test, 11.010,
P = 0.001; Log-rank test, 11.831, P = 0.001). Meanwhile,
the differences of survival in metastasis of lymph node
groups and infiltrative depth groups were also statistically
significant (Table 2). Importantly, there were no significant
differences between the three groups in terms of patient
age, gender and tumor differentiation. The MMP-9 expres-
sion appeared as a significantly independent prognostic fac-
tor (P = 0.008) with a relative risk of 1.857 (95% confidence
interval, 1.117 to 3.088) in Cox multivariate analysis, which
was done with the following variables for each case: MMP-
9 expression, metastasis of lymph node, infiltrative depth,
and Dukes’ stage (Table 3).Relationship between matrix metalloproteinase-9
expression and survival rate of colon cancer patients
The 5-year survival rate for 68 colon cancer patients was
57.4%. The 5-year survival rates for MMP-9 negative and
MMP-9 positive cases were 67.6% and 41.9%, respectively.
The difference of survival rate between the MMP-9
Table 3 Results of Cox multivariate regression factors
Factor Wald value P value
Matrix metalloproteinase-9 (MMP-9) expression 5.698 0.017*
Metastasis of lymph node 0.378 0.539
Infiltrative depth 0.159 0.690
Dukes’ stage 6.597 0.010*
*Statistically significant.
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tistically significant (Log-rank test = 11.010, P = 0.001)
(Figure 2).
Discussion
Colon cancer is one of the most familiar malignant neo-
plasmas. The pathogenesis of tumor is a process of mul-
tiple factors, multiple steps and many stages, which are
concerned with the abnormalities of many oncogenes,
tumor suppressor genes, mismatch repair genes and
cellular adhesive factors [10]. But the invasion and me-
tastasis of tumor cells were main causes for cancer
treatment failure among these factors. MMP-9 is the
most complex member of the MMPs family in terms of
domain structure. It is capable of degrading decorin,
elastin, fibrillin, laminin, gelatin, and types IV, V, XI
and XVI collagen [11,12]. The expression of MMP-9
was regulated by many upstream factors. Levels of
phosphorylated signal transducer and activator of tran-
scription 3(STAT3) regulated the MMP-9 gene in
pediatric patients with ulcerative colitis [13]. Ursolic
acid (UA), a natural pentacyclic triterpenoid carboxylicFigure 2 Kaplan-Meier survival plots of matrix metalloproteinase-9 (M
significant difference in survival rate between the MMP-9 negative group aacid distributed in medical herbs, also suppressed
colon cancer cell migration by inhibiting MMP-9 ex-
pression [14]. Increased CO2 concentration also ele-
vated the mRNA expression of MMP-9 and invasive
capability in colon cancer cell lines and human sam-
ples derived from a peritoneal metastasis [15]. Knock-
down of metastasis-associated in colon cancer 1
(MACC1) expression using shRNA reduced hepatocel-
lular carcinoma Huh7 cell migration and invasion abil-
ities, which were associated with the downregulation
of MMP-9 protein [16]. Detected by using a luciferase
reporter construct and western blots, piwi-like protein
2 (Piwil2) may regulate a 2-kb MMP-9 promoter frag-
ment and apoptotic pathways in colon cancer [17].
Overexpression of MMP-9 has been found to associate
with the invasion and metastasis of cancer [18]. The level
of MMP-9 expression showed a statistically significant
correlation (P < 0.001) with the disease histopathologic
grade, stage, metastatic potential, recurrence potential,
and survival in patients with squamous cell carcinoma of
the larynx. The Kaplan-Meier curve linearly showed the
MMP-9 expression as a predictor of survival to be signifi-
cantly (P < 0.001) associated with survival [19].
The increased MMP-9 expression makes the main
contribution to the invasive potential of squamous cell
cervical carcinomas [20]. Elevated serum MMP-9 corre-
lated with distant metastasis and poor survival in pa-
tients with squamous cell carcinoma (SCC) over either
the head and neck or the esophagus [21]. Elevated serum
MMP-9 level was also associated with reduced disease-
free survival (DFS) of breast cancer [22].MP-9) positive group and negative group. There is highly
nd the MMP-9 positive group (Log-rank test = 11.010, P = 0.001).
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cancer tissues (47/68, 69.1%) was significantly higher than
that in corresponding distal normal mucosa tissues (3/68,
4.4%), and there was a statistically significant difference
(χ2 =64.602, P <0.001) between them. Furthermore, high
levels of MMP-9 expression in colon cancer cells corre-
lated with lymph node metastasis and with Dukes’ stage.
Therefore, these findings suggested that MMP-9 was likely
to play a role in promoting tumor invasion and metastasis.
Meanwhile, Kaplan-Meier analysis showed that the differ-
ences of survival in metastasis of lymph node groups, infil-
trative depth groups, MMP-9 expression group and
Dukes’ stage group were highly statistically significant.
Cox multivariate analysis suggested that MMP-9 might
serve as an independent marker for poor prognosis. Unsal
D et al. reported that MMP-9 expression was character-
ized by poor overall survival and DFS in patients with
Stage II/III rectal carcinoma [23]. Here, our results
showed that MMP-9 might be correlated with the metas-
tasis of lymph node, and its elevated expression might be
an adverse prognostic indicator for the patients of colon
cancer. Although the detailed molecular mechanism in-
volved in this process is less well defined, this study still
has potential clinical benefits. The MMP-9 expression that
could be detected by immunohistochemistry may be a
useful molecular marker to predict the prognosis in colon
cancer patients.
Conclusions
In conclusion, our study suggests that MMP-9 plays an
important role in invasion and metastasis of colon can-
cer, and thus becomes a useful indicator for clinical as-
sessment of tumor biological behavior and prognosis in
colon cancer patients.
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